BIIB News 302.74 10/17/2014 04:30:27 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 302.74 $BIIB

Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals
at Investor's Business Daily - Thu Oct 16, 2:07PM CDT
Medical products giant Baxter International (BAX) beat Q3 earnings estimates and lifted its 2014 organic sales growth guidance Thursday, though it lowered its EPS outlook due to a divestiture. Its stock initially dropped but by early afternoon was up...
BIIB: 302.74 (-2.95), BAX: 68.18 (-0.16), PFE: 27.70 (-0.49)

Sustainability Pays: 3 Green Companies Making Money
Selena Maranjian, The Motley Fool - Motley Fool - Thu Oct 16, 10:00AM CDT
Photo: Flickr user Kevin Dooley . We often imagine that for companies, there's a trade-off between being profitable and being green. We assume that maximum profitability is achieved by ignoring the environment and that green companies have to...
AGN: 178.00 (+0.41), BIIB: 302.74 (-2.95), CAH: 72.13 (-1.10)

IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 28.40 (+2.27), BIIB: 302.74 (-2.95), KITE: 32.56 (+0.71), FWP: 19.00 (+1.50), XENE: (), ATRA: 10.65 (+0.54), VBAY: (), GWB: 18.00 (unch)

Major Averages Pare Losses, Then Head Lower Again
at Investor's Business Daily - Wed Oct 15, 11:01AM CDT
Stocks headed lower again in late-morning trade after paring steep early losses sparked by weak economic data. The S&P 500 and Dow industrials sank 1.5% each, while the Nasdaq was down 1.3%. The tech-heavy index had earlier narrowed its deficit to...
AMBA: 38.76 (+0.16), BIIB: 302.74 (-2.95), CAVM: 43.09 (-0.03), NTES: 88.10 (-0.89), NXPI: 61.06 (+2.45), INTC: 30.85 (-0.42)

Biogen Idec and Gretchen Rubin Unveil MS Blueprint(TM), a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals
Business Wire - Wed Oct 15, 7:01AM CDT
Living with a chronic condition like multiple sclerosis (MS) can be overwhelming for individuals and caregivers who have to balance the challenges of everyday life and work while juggling regular doctors' visits and medications. To support people living with MS, Biogen Idec (NASDAQ:BIIB) has launched MS Blueprint(TM), a new program that encourages those impacted by MS to focus on activities that may bring joy to their lives every day. By visiting MSBlueprint.com, people can set goals, create personalized MS Blueprints, and take small steps toward a more positive life.
BIIB: 302.74 (-2.95)

IBD 50: Medical, Internet Companies Top Q3 Estimates
at Investor's Business Daily - Mon Oct 13, 6:15PM CDT
Health care and Internet companies are expected to have some of the strongest third-quarter profit gains in the IBD 50. The consensus analyst estimates for medical leaders Gilead Sciences (GILD) and Lannett (LCI) exceed 200% growth. The June-quarter...
AMBA: 38.76 (+0.16), BIIB: 302.74 (-2.95), ACT: 222.07 (+4.83), VIPS: 189.33 (+3.65), YY: 76.37 (+3.97), SWKS: 51.53 (+1.93), FB: 72.63 (-0.58), AKRX: 35.80 (+0.85), KSU: 116.41 (+0.84), SLXP: 137.38 (+4.96), ATHM: 46.51 (+1.39), LCI: 41.66 (+1.36), ABC: 75.02 (-1.00), GILD: 96.88 (+0.72), AVGO: 75.60 (+3.05)

Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Isis Pharmaceuticals (ISIS) announced positive results from phase II studies on ISIS-SMNRx.
MDVN: 92.54 (+2.91), BIIB: 302.74 (-2.95), ISIS: 40.56 (+1.59), LGND: 48.86 (+2.58)

SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 4.25% Loss
Comtex SmarTrend(R) - Mon Oct 13, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.99 to a high of $315.75. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $312.00 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 302.74 (-2.95)

IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 28.40 (+2.27), BIIB: 302.74 (-2.95), FWP: 19.00 (+1.50), KITE: 32.56 (+0.71), XENE: (), MRK: 53.43 (-1.30), CFG: 21.80 (-0.05), ZAYO: (), ATRA: 10.65 (+0.54), TEVA: 51.56 (+1.47), VBAY: (), GWB: 18.00 (unch)

Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire
PR Newswire - Mon Oct 13, 7:30AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Arrowhead Research Corp. (NASDAQ: ARWR), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), HCA Holdings, Inc. (NYSE: HCA) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7111-100free.
HCA: 68.23 (+3.39), BIIB: 302.74 (-2.95), ARWR: 7.02 (+0.55), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96)

1 Huge Risk Facing This Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 12, 11:02AM CDT
Source: GW Pharmaceuticals The prospects for medical marijuana are incredibly intriguing. According to a Medical Marijuana Markets report in 2011, the market for medical marijuana may surge from $1.7 billion in that same year to as much as $9...
BIIB: 302.74 (-2.95), GWPH: 63.09 (+1.54), SNY: 50.64 (-0.86), NVS: 85.02 (-1.20)

Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe
Thomson Reuters ONE - Thu Oct 09, 2:01PM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that Biogen Idec has submitted a Marketing Authorisation Application (MAA) for Elocta (rFVIIIFc) to the European Medicines Agency (EMA). Sobi has an exclusive opt-in right to assume final development and commercialisation of Elocta in Europe, Russia, the Middle East and Northern Africa.
BIIB: 302.74 (-2.95)

Global Biological Drugs Market Outlook 2020
M2 - Thu Oct 09, 2:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sv5tsf/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb) and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. On the other hand, high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market. Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/sv...ical_drugs
BIIB: 302.74 (-2.95), ABT: 39.99 (-0.02), BAX: 68.18 (-0.16), PFE: 27.70 (-0.49), MRK: 53.43 (-1.30), AMGN: 130.45 (-0.45), LLY: 61.90 (-0.97), GSK: 42.88 (-0.25), BMY: 49.22 (+0.26), NVS: 85.02 (-1.20)

CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Business Wire - Wed Oct 08, 3:01PM CDT
Second paragraph, first sentence of release dated September 25, 2014 should read: Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. (instead of Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 9:00 am ET.).
BIIB: 302.74 (-2.95)

5 States Expected to See the Biggest Increase in Alzheimer's Disease
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 05, 10:07AM CDT
Source: Centers for Disease Control and Prevention. Cancer and heart disease may be far more prevalent killers, but Alzheimer's disease is certainly no ailment to overlook, considering that it's the eighth leading cause of death in the United...
BIIB: 302.74 (-2.95), ACT: 222.07 (+4.83), PFE: 27.70 (-0.49), LLY: 61.90 (-0.97)

The Next Blue-Chip Stocks: Biogen Idec
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 04, 10:32AM CDT
Becoming the next blue chip stock isn't easy, especially in a high risk, high reward sector like biotech. But once you get to be as big as Biogen Idec , blue chip status is the next obvious step. BIIB data by YCharts Solid revenue...
BIIB: 302.74 (-2.95), AMGN: 130.45 (-0.45)

Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 3:45PM CDT
Perrigo (PRGO) has out licensed some of its early-stage assets.
BIIB: 302.74 (-2.95), PRGO: 145.69 (-0.16), ABAX: 48.10 (+0.03), HAE: 34.98 (-0.64)

Insider Trading Alert - BIIB, RKUS And PF Traded By Insiders
at The Street - Fri Oct 03, 9:30AM CDT
Stocks with insider trader activity include BIIB, RKUS and PF
BIIB: 302.74 (-2.95), PF: 31.85 (-0.27), RKUS: 11.68 (unch)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 143

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 31

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 92

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 168

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 15

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 91

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 195

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading

Top 5 Most Recently Viewed Articles

New Leadership at KeyCorp: A Strategic Move for Risk Management

Updated Category News Views 304

KeyCorp Welcomes Mohit Ramani as Chief Risk Officer KeyCorp (NYSE: KEY), a prominent figure in the bank-based financial services industry, has made an important decision by announcing the appointment of Mohit (Mo) Ramani as its new Chief Risk Officer. This notable addition to the executive leadership team is seen as a strategic step towards enhancing the company's risk...

Continue Reading
Quaternary Ammonium Salts Market Expanding: Insights Ahead

Updated Category News Views 152

Exploring the Growth of the Quaternary Ammonium Salts Market The global quaternary ammonium salts market is on a remarkable growth trajectory, anticipated to reach a valuation of US$ 1,088.0 Million by the year 2034. With a robust CAGR of 5.9% from 2024 to 2034, this market is driven by increasing consumer awareness regarding hygiene and safety. Factors Driving Market...

Continue Reading
Generac's Upcoming Earnings: Key Details and Expectations

Updated Category News Views 147

Generac Prepares for Earnings Release and Conference Call Generac Holdings Inc. (NYSE: GNRC), known as a prominent leader in energy technology solutions, is gearing up for an important announcement. The company plans to unveil its fourth quarter and full-year 2024 financial results just before the market opens. The anticipated date for this release is set for an upcoming...

Continue Reading
AAVantgarde Ready for Key Presentations at EURetina 2025

Updated Category News Views 207

Significant Presentation at EURetina 2025 AAVantgarde Bio, a leading clinical-stage biotechnology company, is poised to present updated outcomes from its LUCE-1 clinical trial at the prestigious 25th European Society of Retina Specialists (EURETINA) Annual Congress in Paris. This event, scheduled from September 4-7, 2025, offers a vital platform for advancing discussions...

Continue Reading
Investing in WisdomTree Funds: Insights on Value and Performance

Updated Category News Views 246

Understanding the Value of WisdomTree Funds WisdomTree is known for its innovative approach to exchange-traded funds (ETFs). As investors seek ways to maximize their asset portfolios, understanding the net asset values (NAVs) of these funds becomes essential. In this article, we delve into various funds offered by WisdomTree, highlighting their date of valuation and key...

Continue Reading